A phase 3, multicenter, randomized, open-label study of ifinatamab deruxtecan (I-DXd), a b7-h3 antibody drug conjugate (ADC), versus treatment of physician’s choice (TPC) in subjects with relapsed small cell lung cancer (SCLC)
Phase: Phase III clinical trials
Principal Investigator: Dott.ssa Proto Claudia
Main Facility: Oncologia Medica Toraco-Polmonare
Drug: Ifinatamab Deruxtecan (I-DXd)
Pathologies: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
A global Phase 3 clinical trial in patients with relapsed small cell lung cancer (SCLC), which aims to evaluate the safety and efficacy of a new drug called Ifinatamab Deruxtecan (I-DXd) by comparing two different treatment arms. Upon participation, patients will be randomly assigned (1:1 randomization) to only one of them, in order to compare the study drug with the standard therapy:
Arm A (Experimental Arm): Ifinatamab Deruxtecan (I-DXd), an antibody-drug conjugate (ADC) designed to specifically target tumor cells expressing the B7-H3 protein and destroy them from the inside.
Arm B (Control Arm): Treatment of physician's choice (among the drugs topotecan, amrubicin, or lurbinectedin), which represents the current standard chemotherapy for this condition.
The study targets patients whose disease has relapsed or progressed after already receiving a first-line therapeutic treatment based on platinum (with or without immunotherapy).
Last update: 13/07/2026